Tags

Type your tag names separated by a space and hit enter

[Comparison of autologous and allogeneic hematopoietic stem cell transplantation for 140 patients with de novo acute leukemia in first complete remission].
Zhonghua Xue Ye Xue Za Zhi. 2004 Jul; 25(7):389-92.ZX

Abstract

OBJECTIVE

To evaluate the outcome of patients with de novo acute leukemia (AL, no AML-M(3)) in CR(1) undergone autologous hematopoietic stem cell transplantation (auto-HSCT) or HLA-identical sibling allogeneic HSCT (allo-HSCT).

METHODS

Forty-six AL patients received allo-HSCT and 94 received auto-HSCT in CR(1). The conditioning regimens mainly consisted of TBICy, BuCy and MAC. Cyclosporine plus methotrexate, or cyclosporine alone, or FK506 alone was used for graft-versus-host disease (GVHD) prophylaxis. Among auto-HSCT group, 39 patients received purged autologous bone marrow and 38 received immunotherapy and/or maintenance chemotherapy after transplant.

RESULTS

Myeloid reconstitution was achieved in all patients. After a median of 700 (range, 18 approximately 5563) days follow-up, the probabilities of leukemia-free survival (LFS) at 5 year were not significantly different in these two groups: (51.5 +/- 5.4)% for auto-HSCT group and (52.8 +/- 7.6)% for allo-HSCT group (P > 0.05). There was a lower cumulative relapse incidence (RI) [(26.3 +/- 6.9)% vs. (52.0 +/- 5.5)%, P > 0.05] but a significantly higher cumulative transplant-related mortality (TRM) [(37.6 +/- 7.8% vs. (14.4 +/- 4.1)%, P < 0.05] in the allo-HSCT group than in auto-HSCT group. Among auto-HSCT group, the patients received purged autografts and/or post-transplant therapy had significantly better LFS and lower RI (P < 0.05) than those received unpurged autografts or no post-transplant treatments [5-y LFS: (62.8 +/- 6.8)% and (38.4 +/- 8.4)%; RI: (37.7 +/- 6.8)% and (74.2 +/- 8.7)%, respectively].

CONCLUSION

The long-term LFS of auto-HSCT was comparable to that of allo-HSCT in the management of patients with AL in CR(1), because autograft purging and post-transplant treatment can significantly decrease relapse of auto-HSCT patients and auto-HSCT has lower therapy-related toxicities.

Authors+Show Affiliations

Institute of Hematology and Blood Diseases Hospital, CAMS and PUMC, Tianjin 300020, China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
English Abstract
Journal Article

Language

chi

PubMed ID

15355688

Citation

Wang, He-hua, et al. "[Comparison of Autologous and Allogeneic Hematopoietic Stem Cell Transplantation for 140 Patients With De Novo Acute Leukemia in First Complete Remission]." Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi, vol. 25, no. 7, 2004, pp. 389-92.
Wang HH, Feng SZ, Wang M, et al. [Comparison of autologous and allogeneic hematopoietic stem cell transplantation for 140 patients with de novo acute leukemia in first complete remission]. Zhonghua Xue Ye Xue Za Zhi. 2004;25(7):389-92.
Wang, H. H., Feng, S. Z., Wang, M., Wei, J. L., Jiang, E. L., Zhang, L., Huang, Y., Zhou, S. Y., Liu, Q. G., Qiu, L. G., Han, M. Z., & Yan, W. W. (2004). [Comparison of autologous and allogeneic hematopoietic stem cell transplantation for 140 patients with de novo acute leukemia in first complete remission]. Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi, 25(7), 389-92.
Wang HH, et al. [Comparison of Autologous and Allogeneic Hematopoietic Stem Cell Transplantation for 140 Patients With De Novo Acute Leukemia in First Complete Remission]. Zhonghua Xue Ye Xue Za Zhi. 2004;25(7):389-92. PubMed PMID: 15355688.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Comparison of autologous and allogeneic hematopoietic stem cell transplantation for 140 patients with de novo acute leukemia in first complete remission]. AU - Wang,He-hua, AU - Feng,Si-zhou, AU - Wang,Mei, AU - Wei,Jia-lin, AU - Jiang,Er-lie, AU - Zhang,Li, AU - Huang,Yong, AU - Zhou,Shi-yong, AU - Liu,Qing-guo, AU - Qiu,Lu-gui, AU - Han,Ming-zhe, AU - Yan,Wen-wei, PY - 2004/9/10/pubmed PY - 2008/5/6/medline PY - 2004/9/10/entrez SP - 389 EP - 92 JF - Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi JO - Zhonghua Xue Ye Xue Za Zhi VL - 25 IS - 7 N2 - OBJECTIVE: To evaluate the outcome of patients with de novo acute leukemia (AL, no AML-M(3)) in CR(1) undergone autologous hematopoietic stem cell transplantation (auto-HSCT) or HLA-identical sibling allogeneic HSCT (allo-HSCT). METHODS: Forty-six AL patients received allo-HSCT and 94 received auto-HSCT in CR(1). The conditioning regimens mainly consisted of TBICy, BuCy and MAC. Cyclosporine plus methotrexate, or cyclosporine alone, or FK506 alone was used for graft-versus-host disease (GVHD) prophylaxis. Among auto-HSCT group, 39 patients received purged autologous bone marrow and 38 received immunotherapy and/or maintenance chemotherapy after transplant. RESULTS: Myeloid reconstitution was achieved in all patients. After a median of 700 (range, 18 approximately 5563) days follow-up, the probabilities of leukemia-free survival (LFS) at 5 year were not significantly different in these two groups: (51.5 +/- 5.4)% for auto-HSCT group and (52.8 +/- 7.6)% for allo-HSCT group (P > 0.05). There was a lower cumulative relapse incidence (RI) [(26.3 +/- 6.9)% vs. (52.0 +/- 5.5)%, P > 0.05] but a significantly higher cumulative transplant-related mortality (TRM) [(37.6 +/- 7.8% vs. (14.4 +/- 4.1)%, P < 0.05] in the allo-HSCT group than in auto-HSCT group. Among auto-HSCT group, the patients received purged autografts and/or post-transplant therapy had significantly better LFS and lower RI (P < 0.05) than those received unpurged autografts or no post-transplant treatments [5-y LFS: (62.8 +/- 6.8)% and (38.4 +/- 8.4)%; RI: (37.7 +/- 6.8)% and (74.2 +/- 8.7)%, respectively]. CONCLUSION: The long-term LFS of auto-HSCT was comparable to that of allo-HSCT in the management of patients with AL in CR(1), because autograft purging and post-transplant treatment can significantly decrease relapse of auto-HSCT patients and auto-HSCT has lower therapy-related toxicities. SN - 0253-2727 UR - https://www.unboundmedicine.com/medline/citation/15355688/[Comparison_of_autologous_and_allogeneic_hematopoietic_stem_cell_transplantation_for_140_patients_with_de_novo_acute_leukemia_in_first_complete_remission]_ L2 - http://journal.yiigle.com/LinkIn.do?linkin_type=pubmed&amp;issn=0253-2727&amp;year=2004&amp;vol=25&amp;issue=7&amp;fpage=389 DB - PRIME DP - Unbound Medicine ER -